SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs

Related Keywords

Temple University , Pennsylvania , United States , Philadelphia , America , American , Corey Davis , Veronica Eames , Mark Sulkowski , Exchange Commission On , Temple University School Of Medicine , American Association Of Liver Disease On , Medicine At Duke University School Of , Exchange Commission , Johns Hopkins University School Of Medicine , Lifesci Communications , Viral Hepatitis Center , Nasdaq , Department Of Medicine , Infectious Diseases Society Of America , Clinical Trials Group , American Society For Clinical Investigation , American Association Of Physicians , Aligos Therapeutics Inc , Johns Hopkins University School , Late Breaking , Liver Meeting , American Association , Liver Disease , Infectious Diseases , Johns Hopkins Bayview Medical , Medical Director , Senior Associate Dean , Temple University School , Internal Medicine , Duke University School , New England Journal , Hepatitis Transformative Sciences Group , National Institute , Trials Group , American Society , Clinical Investigation , Liver Diseases , European Association , Infectious Diseases Society , Clinical Infectious Diseases , Highly Cited Researcher , Clarivate Analytics , Securities Litigation Reform Act , Aligo Quarterly Report , Region ,